乌体林斯对慢性阻塞性肺病患者免疫功能的影响  

Effect of Mycobacterium Phlei F. U. 36 on Immunologic Function of COPD Patients

作　　者：李维欣[1] 施永美[1] 朱睛辉[2] 蒋毋右[1] 

机构地区：[1]上海市普陀区人民医院呼吸内科,上海200060 [2]上海市普陀区人民医院免疫室,上海200060

出　　处：《医学临床研究》2010年第12期2222-2223,2226,共3页Journal of Clinical Research

摘　　要：【目的】研究乌体林斯注射液对慢性阻塞性肺病（COPD）稳定期患者免疫功能的影响及，临床意义。【方法】将COPD稳定期患者随机分为乌体林斯治疗组和对照组，对比两组患者用药前后急性加重的发病频率、住院次数及血清CD3＋、CD4＋、CD8＋及CD4＋／CD8＋的变化。【结果】乌体林斯治疗组较对照组患者急性加重发病频率、住院次数明显减少，治疗组用药前后比较血清CD4＋及CD4＋／CD8＋水平有明显增加；和对照组比较亦有明显增加。【结论】乌体林斯能提高COPD患者的免疫功能，减少COPD急性加重频率，减少住院次数，提高生活质量，是一种良好的免疫调节剂，值得临床推广使用。[Objective]To study the effect of mycobacterium phlei F. U. 36 on the immunologic function of chronic obstructive pulmonary disease（COPD） patients in stable phase and its significance. [Methods] COPD patients in stable phase were divided into mycobacterium phlei F. U. 36 therapeutic group and control group randomly. The acute exacerbation onset frequency, number of hospitalization and the changes of serum CD3 ＋ , CD4＋, CD8＋ and CD4＋/CD8＋ ratio were compared between two groups before and after medication. [Results] Compared with the control group, the onset frequency and number of hospitalization in mycobacterium phlei F. U. 36 therapeutic group significantly decreased. Compared with before medication, serum CD4＋ and CD4＋/CD8＋ ratio significantly increased after treatment in mycobacterium phlei F. U. 36 therapeutic group. Compared with the control group, serum CD4＋ and CD4＋/CD8＋ ratio also increased obviously. [Conclusion] Mycobaeterium phlei F. U. 36 can increase the immunologic function of COPD patients, and decrease the frequency of acute exacerbation and number of hospitalization, and improve the quality of life. Therefore, it is a good immunomodulator and worthy of being spread in clinics.

关 键 词：肺疾病 阻塞性 慢性病 分枝杆菌 草 

分 类 号：R563.9[医药卫生—呼吸系统]